Pharmacoeconomic Analysis Of Everolimus Immunosupressive Therapy After Renal Transplantation.

Pharmacoeconomic Analysis of the use of Everolimus Compared to Axitinib in Second Line Therapy of Patients with Metastatic Renal Cell Carcinoma.

Combination therapy with everolimus and tacrolimus in kidney transplantation recipients: A systematic review

Background and aims: Immunosuppressive regimens are a key component for successful kidney transplantation. This systematic review aimed to assess the efficacy and safety of combination therapy of everolimus with tacrolimus in kidney transplantation recipients. Methods: Results were limited to English-language articles. Trials where recipients received ano...

Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients.

OBJECTIVES We examined the experiences of heart transplant recipients receiving everolimus as maintenance therapy in different combinations over a long time. MATERIALS AND METHODS Between 2004 and 2009, forty patients (29 men, 11 women; mean age, 51.6 y) were switched from a routine immunosuppressive regimen to everolimus. Indications were other (2), renal insufficiency (17), cardiac allograf...

Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients

BACKGROUND We tested the strategy of mTOR inhibitors with calcineurin inhibitor minimization in renal transplant recipients with known chronic allograft dysfunction. METHODS In this open-label, single-arm study, renal transplant patients were recruited after biopsy-confirmed chronic allograft dysfunction in the absence of acute rejection episode within 2 months, with proteinuria <0.8 g/day, a...

Everolimus in Heart Transplantation: An Update

The evidence base relating to the use of everolimus in heart transplantation has expanded considerably in recent years, providing clinically relevant information regarding its use in clinical practice. Unless there are special considerations to take into account, all de novo heart transplant patients can be regarded as potential candidates for immunosuppression with everolimus and reduced-expos...